Krystal Biotech, Inc.
↗Pittsburgh, USA
Krystal Biotech is a commercial-stage biotechnology company focused on the discovery, development, and commercialization of genetic medicines for patients with rare diseases. The company utilizes its proprietary, redosable HSV-1-based gene therapy platform to deliver therapeutic transgenes to target cells.
Headquartered in Pittsburgh, Pennsylvania, Krystal Biotech is a fully integrated company with core capabilities in viral vector design, optimization, manufacturing, and commercialization. Its lead product, VYJUVEK (beremagene geperpavec-svdt), is the first-ever redosable gene therapy approved by the FDA for the treatment of dystrophic epidermolysis bullosa (DEB).
CLASSIFICATION
SIZE & FINANCIALS
Employees:201-500
Revenue:$300M-$400M
Founded:2016
Ownership:public
Status:operating
FUNDING
Stage:Post-IPO
Investors:EB Research Partnership
STOCK
Exchange:NASDAQ
Ticker:KRYS
Market Cap:$7.36B
PIPELINE
Stage:Commercial
Lead Drug Stage:Commercial
Modalities:Gene therapy
Trial Phases:-
FDA Approvals:1
EMA Approvals:1
CORPORATE STRUCTURE
Subsidiaries:Jeune Aesthetics
COMPETITION
Position:Leader
Competitors:Vertex Pharmaceuticals, Replimune
LEADERSHIP
Key Executives:
Krish Krishnan - Chairman & CEO
Suma Krishnan - President, Research & Development
Scientific Founders:Suma Krishnan
LINKS
Website:krystalbio.com
LinkedIn:LinkedIn Profile
⚠
Is this information incorrect? This profile was AI-generated from publicly available sources and may contain errors. If you are a representative of Krystal Biotech, Inc. and believe any information on this page is inaccurate, we will promptly correct or remove it.REPORT AN ERROR
Disclaimer: IntuitionLabs.ai is not affiliated with, endorsed by, or associated with Krystal Biotech, Inc.. The information on this page was compiled using AI from publicly available sources and may be incomplete, outdated, or contain errors. We are committed to correcting inaccuracies promptly upon notice. For official information, please visit the company's website directly.